Kyverna Therapeutics, Inc. Increase (Decrease) in Employee Related Liabilities
Kyverna Therapeutics, Inc. (KYTX) reported Increase (Decrease) in Employee Related Liabilities of -$4.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities · last filed 2026-08-11
- Kyverna Therapeutics, Inc. increase (decrease) in employee related liabilities for the quarter ending 2026-06-30 was $2.37M, a 25.11% increase year-over-year.
- Kyverna Therapeutics, Inc. increase (decrease) in employee related liabilities for the quarter ending 2026-03-31 was -$6.88M.
- Kyverna Therapeutics, Inc. increase (decrease) in employee related liabilities for the quarter ending 2025-12-31 was $3.03M, a 583.97% increase year-over-year.
- Kyverna Therapeutics, Inc. increase (decrease) in employee related liabilities for the quarter ending 2025-09-30 was $1.99M, a 15.77% increase year-over-year.
- Kyverna Therapeutics, Inc. increase (decrease) in employee related liabilities for fiscal 2025 was $5.11M, a 146.60% increase from fiscal 2024.
- Kyverna Therapeutics, Inc. increase (decrease) in employee related liabilities for fiscal 2024 was $2.07M, a 47.82% increase from fiscal 2023.
- Kyverna Therapeutics, Inc. increase (decrease) in employee related liabilities for fiscal 2023 was $1.40M.
| Period end | Increase (Decrease) in Employee Related Liabilities 3 month | Increase (Decrease) in Employee Related Liabilities 6 month | Increase (Decrease) in Employee Related Liabilities 9 month | Increase (Decrease) in Employee Related Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$4.51M 10-Q · filed 2026-08-11 | -$1.48M derived: sum of 3 quarters · filed 2026-08-11 | $510.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$6.88M 10-Q · filed 2026-05-12 | -$3.85M derived: sum of 2 quarters · filed 2026-05-12 | -$1.86M derived: sum of 3 quarters · filed 2026-05-12 | $35.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $3.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $5.02M derived: sum of 2 quarters · filed 2026-03-26 | $6.91M derived: sum of 3 quarters · filed 2026-08-11 | $5.11M 10-K · filed 2026-03-26 |
| 2025-09-30 | $1.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.88M derived: sum of 2 quarters · filed 2026-08-11 | $2.08M 10-Q · filed 2025-11-12 | $2.52M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $88.00K 10-Q · filed 2026-08-11 | $531.00K derived: sum of 3 quarters · filed 2026-08-11 | $2.25M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$1.80M 10-Q · filed 2026-05-12 | -$1.36M derived: sum of 2 quarters · filed 2026-05-12 | $357.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.72M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $443.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.16M derived: sum of 2 quarters · filed 2026-03-26 | $3.52M derived: sum of 3 quarters · filed 2026-03-26 | $2.07M 10-K · filed 2026-03-26 |
| 2024-09-30 | $1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.08M derived: sum of 2 quarters · filed 2025-11-12 | $1.63M 10-Q · filed 2025-11-12 | $2.58M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$90.00K 10-Q · filed 2025-08-12 | $867.00K derived: sum of 3 quarters · filed 2025-08-12 | $1.59M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$1.45M 10-Q · filed 2025-05-13 | -$492.00K derived: sum of 2 quarters · filed 2025-05-13 | $227.00K derived: sum of 3 quarters · filed 2025-05-13 | $729.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $957.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.68M derived: sum of 2 quarters · filed 2025-03-27 | $2.18M derived: sum of 3 quarters · filed 2025-03-27 | $1.40M 10-K · filed 2025-03-27 |
| 2023-09-30 | $719.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.22M derived: sum of 2 quarters · filed 2024-11-13 | $444.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $502.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$275.00K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | -$777.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |